Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-7367
- Development stage
- Phase 2
- Lead developer
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-7367 is a bispecific antibody designed to target both fibroblast activation protein alpha (FAP), which is predominantly expressed on cancer-associated fibroblasts in the tumor stroma, and CD40, a stimulatory receptor found on various immune cells such as B lymphocytes, monocytes, and dendritic cells. By binding to FAP and CD40, SHR-7367 aims to modulate the tumor microenvironment by disrupting stromal support for tumors while simultaneously activating immune responses against cancer cells. The drug is being developed primarily for the treatment of advanced malignant solid tumors and neoplasms[1][2].
- Other names
- FAP/CD40-targeting agent SHR-7367
02
Targets
FAP (Fibroblast activation protein alpha)CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on SHR-7367.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-7367.